Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31,406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Yao JC, et al. Among authors: singh s. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. Lancet. 2016. PMID: 26703889 Free PMC article. Clinical Trial.
Uncommon Anal Neoplasms.
Roy AC, Wattchow D, Astill D, Singh S, Pendlebury S, Gormly K, Segelov E. Roy AC, et al. Among authors: singh s. Surg Oncol Clin N Am. 2017 Jan;26(1):143-161. doi: 10.1016/j.soc.2016.07.009. Surg Oncol Clin N Am. 2017. PMID: 27889033 Review.
Everolimus in the management of metastatic neuroendocrine tumours.
Chan DL, Segelov E, Singh S. Chan DL, et al. Among authors: singh s. Therap Adv Gastroenterol. 2017 Jan;10(1):132-141. doi: 10.1177/1756283X16674660. Epub 2016 Oct 25. Therap Adv Gastroenterol. 2017. PMID: 28286565 Free PMC article. Review.
Prognostic and predictive biomarkers in neuroendocrine tumours.
Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, Pavlakis N. Chan DL, et al. Among authors: singh s. Crit Rev Oncol Hematol. 2017 May;113:268-282. doi: 10.1016/j.critrevonc.2017.03.017. Epub 2017 Mar 18. Crit Rev Oncol Hematol. 2017. PMID: 28427516 Review.
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.
Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group. Singh S, et al. Neuroendocrinology. 2018;106(3):211-220. doi: 10.1159/000477585. Epub 2017 May 24. Neuroendocrinology. 2018. PMID: 28554173 Clinical Trial.
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. Strosberg JR, et al. Among authors: singh s. Pancreas. 2017 Jul;46(6):707-714. doi: 10.1097/MPA.0000000000000850. Pancreas. 2017. PMID: 28609356 Free PMC article. Review.
31,406 results
You have reached the last available page of results. Please see the User Guide for more information.